Analyzing Recordati Industria Chimica E Farmaceutica (RCDTF) and Its Rivals

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) is one of 245 publicly-traded companies in the “MED – DRUGS” industry, but how does it weigh in compared to its rivals? We will compare Recordati Industria Chimica E Farmaceutica to similar businesses based on the strength of its risk, earnings, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Volatility & Risk

Recordati Industria Chimica E Farmaceutica has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Recordati Industria Chimica E Farmaceutica’s rivals have a beta of 0.57, indicating that their average stock price is 43% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Recordati Industria Chimica E Farmaceutica and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recordati Industria Chimica E Farmaceutica	1	1	0	0	1.50
Recordati Industria Chimica E Farmaceutica Competitors	1228	3384	9168	329	2.61

As a group, “MED – DRUGS” companies have a potential upside of 154.13%. Given Recordati Industria Chimica E Farmaceutica’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Recordati Industria Chimica E Farmaceutica has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares Recordati Industria Chimica E Farmaceutica and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Recordati Industria Chimica E Farmaceutica	$2.53 billion	$450.70 million	32.72
Recordati Industria Chimica E Farmaceutica Competitors	$1.08 billion	$57.59 million	-5.93

Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than its rivals. Recordati Industria Chimica E Farmaceutica is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Recordati Industria Chimica E Farmaceutica and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recordati Industria Chimica E Farmaceutica	N/A	N/A	N/A
Recordati Industria Chimica E Farmaceutica Competitors	-20,305.47%	-74.68%	-24.21%

Insider & Institutional Ownership

44.2% of shares of all “MED – DRUGS” companies are owned by institutional investors. 13.9% of shares of all “MED – DRUGS” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Recordati Industria Chimica E Farmaceutica rivals beat Recordati Industria Chimica E Farmaceutica on 7 of the 13 factors compared.

Recordati Industria Chimica E Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.